AGRICULTURAL AND FOOD CHEMISTRY

Synthesis and Antifungal Activity of 2-Chloromethyl-1*H*benzimidazole Derivatives against Phytopathogenic Fungi in Vitro

Yu-Bin Bai, An-Ling Zhang,* Jiang-Jiang Tang, and Jin-Ming Gao*

Shaanxi Engineering Center of Bioresource Chemistry & Sustainable Utilization, College of Science, Northwest A&F University, Yangling, Shaanxi 712100, People's Republic of China

Supporting Information

ABSTRACT: A series of 35 benzimidazole derivatives were synthesized from 2-chloromethyl-1*H*-benzimidazole in good yields. Their structures were characterized by ¹H and ¹³C NMR and HRESIMS. Antifungal activities of all of the synthesized compounds were evaluated against five phytopathogens fungi (*Cytospora* sp., *Colletotrichum gloeosporioides*, *Botrytis cinerea*, *Alternaria solani*, and *Fusarium solani*) using the mycelium growth rate method. Compound **4m** displayed strong growth inhibition of *C. gloeosporioides*, *A. solani*, and *F. solani* with IC₅₀ of 20.76, 27.58, and 18.60 μ g/mL, respectively. Selective inhibition of *B. cinerea* instead of the other fungal pathogenes was observed with 7f (IC₅₀ of 13.36 μ g/mL), comparable to that of positive control, a commercial agricultural fungicide hymexazol (IC₅₀ of 8.92 μ g/mL). Compound **5b** exhibited remarkable antifungal properties against *Cytospora* sp., *C. gloeosporioides*, *B. cinerea*, and *F. solani* with IC₅₀ values of 30.97, 11.38, 57.71, and 40.15 μ g/mL, respectively; among the target fungi, **5b** was the most active compound and superior to the reference against *C. gloeosporioides* alone. Structure–activity relationship (SAR) data of these compounds are as follows: (1) introduction of the chlorine atom on para-position in the benzene ring help to increase activity (**4f** vs **4c**; 7f vs **7n**), (2) the sulfonyl group is critical for the inhibition of *C. gloeosporioides* (**5b** and **5c** vs **5a**), and (3) the unsubstituted benzene ring improve activity (**4m** vs **4n**, **4e** and **4a**). Thus, compounds **5b**, **4m**, and **7f** emerged as a new leading structure for the development of new fungicides.

KEYWORDS: synthesis, 2-chloromethyl-1H-benzimidazole derivatives, antifungal activity, phytopathogenic fungi, structure–activity relationship

INTRODUCTION

Plant diseases are caused primarily by fungal and bacterial pathogens, leading to severe losses to agriculture and horticulture crop production worldwide and constitute an emerging threat to the global food security.¹ Considerable postharvest losses of fruits and vegetables occur by decay caused by fungal pathogens, which, in addition to causing rot, may produce mycotoxins capable of the harmful consequences on animal and human health.^{2–5} As a result, several important fungal plant pathogens of the genera Colletotrichum, Botrytis, Alternaria, and Fusarium have received great attention due to their typical infected disease symptoms (e.g., postharvest diseases of fruits such as anthracnose caused by Colletotrichum species).^{3,4} Many of the currently available antifungal agents have several drawbacks, such as drug related toxicity, severe drug resistance, nonoptimal pharmacokinetics, and serious drug interactions.⁶ Therefore, there is a growing need to develop new antifungal agents to effectively control those agricultural diseases.

Benzimidazole is one of the commonly used chemical scaffolds because it plays an important role in medicinal chemistry and agrochemicals; it has earned an essential place in the list of chemotherapeutic agents. During the past 5–10 years, many condensation products of benzimidazole have been patented for a variety of biological activities, such as antitumor, antiinflammatory, antiviral, and antifungal.^{7–9} Extensive biochemical and pharmacological studies have confirmed that benzimidazole molecules are effective against various strains of microorganisms.⁸ Especially, benzimidazole is a core substructure of systemic fungicides currently

in use for controlling mycoses in humans.⁷ Similarly, 2-substituted benzimidazole and its derivatives have been found to be potent biologically active compounds as well. The activity and structural diversity exhibited by compounds containing the benzimidazole moiety has led to the development of a series of novel and useful bioactive benzimidazole analogs.⁹

In our previous work, acetophenone derivatives were designed and synthesized,¹⁰ and some compounds showed diverse and promising bioactivities such as fungicidal and antitumor activities. In continuation of our investigation on the design and synthesis of bioactive compounds, a series of novel analogs of 2-chloromethyl-1*H*-benzimidazole were designed and synthesized from the intermediates 2-chloromethyl-1*H*-benzimidazole and 2-chloromethyl-1-methyl-5-nitro-1*H*-benzimid-azole via an efficient method (Scheme 1). Their antifungal effects on selected five target phytopathogenic fungi were investigated, and their structureantifungal activity relationships were also discussed. To our knowledge, the antifungal activities of all the synthetic derivatives including known compounds were reported for the first time.

MATERIALS AND METHODS

General Experimental Procedures. The melting points of the products were determined on an X-4 apparatus (Beijing Tech Instrument Co., Beijing, P. R. China) and are uncorrected. Nuclear magnetic resonance

| Received: | December 17, 2012 |
|------------|-------------------|
| Revised: | February 17, 2013 |
| Accepted: | February 18, 2013 |
| Published: | February 18, 2013 |

ACS Publications © 2013 American Chemical Society

Scheme 1. Synthetic Route of 2-Chloromethyl-1H-benzimidazole Derivatives^a



^{*a*}Reagents and conditions: (a) HCl, reflux; (b) toluene, (CH₃O)₂SO₂, reflux; (c) triethylamine, acetone, acyl chloride, 0 °C; (d) K₂CO₃, acetone, phenols, reflux, 60 °C.

| R ₁ = | R ₂ = |
|---|--|
| 4a: $-C_6H_4$ -COCH ₃ (m) | 5a: –Ac |
| 4b: $-C_6H_4$ -COCH ₃ (o) | 5b: -O ₂ SCH ₃ |
| 4c: $-C_6H_4$ -COCH ₃ (p) | 5c: $-O_2SC_6H_4Cl(p)$ |
| 4d: $-C_6H_4$ -COOCH ₂ CH ₂ CH ₃ (p) | R ₃ = |
| 4e: $-C_6H_4-F(p)$ | 7a: $-C_6H_4$ -COCH ₃ (m) |
| 4f: $-C_6H_4$ -Cl (p) | 7 b : $-C_6H_4$ -COCH ₃ (o) |
| 4g: -C ₆ H ₄ -CHO (p) | $7c: -C_6H_4 - COCH_3(p)$ |
| 4h: -C ₆ H ₃ -OCH ₃ (<i>o</i>)-CH ₂ CH=C H ₂ (p) | $7d: -C_6H_4$ -COOCH ₂ CH ₂ CH ₃ (p) |
| 4i: –naphthylene (a) | $7e: -C_6H_4 - F(p)$ |
| 4j : $-C_6H_4$ -COOCH ₂ CH ₃ (p) | $7f: -C_6H_4 - Cl(p)$ |
| 4k: $-C_6H_4$ -COOCH ₃ (p) | 7 g : −C ₆ H ₄ −CHO (p) |
| 41: $-C_6H_4-C(CH_3)_3$ (p) | 7h: $-C_6H_3$ -OCH ₃ (o)-CH ₂ CH=C H ₂ (p) |
| 4m : $-C_6H_5$ | 7i: —naphthylene (a) |
| 4n : $-C_6H_3-(-OCH_2O-)(m,p)$ | 7 j : -C ₆ H ₄ -COOCH ₂ CH ₃ (p) |
| 4o: $-C_6H_3$ -OCH ₃ (<i>o</i>)-CHO(p) | $7\mathbf{k}$: $-C_6H_4$ -COOCH ₃ (p) |
| 4p: -C ₆ H ₃ -OCH ₃ (<i>o</i>)-OCCH ₃ (p) | 71: $-C_6H_4 - C(CH_3)_3$ (p) |
| 4q: $-C_6H_4-NO_2$ (p) | 7m: $-C_6H_5$ |
| | 7 n : $-C_6H_3-(-OCH_2O-)(m,p)$ |
| | |

(NMR) spectra were recorded on a Bruker Avance spectrometer (Unity plus 400 or 500 MHz) (Bruker Bios pin, Rheinstetten, Germany) with tetramethylsilane (TMS) as internal standard. Chemical shift values (δ) were given in parts per million (ppm). Thin-layer chromatography (TLC) was performed on silica gel 60 F₂₅₄ (Qingdao Marine Chemical Ltd., P. R. China). Column chromatography (CC) was performed over silica gel (200–300 mesh, Qingdao Marine Chemical Ltd.), High resolution electrospray ionization mass spectrometry (HRESIMS) data were recorded on LCMS-IT-TOF (Shimadzu, Kyoto, Japan). Commercial solvents and reagents were of reagent grade.

General Synthetic Procedure for the Key Intermediates. Intermediates 1 and 6 were synthesized from *o*-phenylenediamine using the reported procedure.^{11–15} Intermediate 2 was synthesized according to reported literature.¹¹

Synthesis of 2-Chloromethyl-1H-benzimidazole (1) by Conventional Method. A mixture of o-phenylenediamine (7.56 g, 80 mmol) and chloroacetic acid (7.56 g, 70 mmol) was taken in a solution of 5 N HCl (60 mL), refluxed in oil bath for 8 h. The reaction mixture was then cooled to room temperature and neutralized with ammonia, till neutral to pH. A yellow residue was obtained by filtration and washed with water.^{11,12} Purification by CC on silica gel eluting with petroleum ether (PE)-acetone (3:1) gave 1 as a yellow solid (9.23 g, yield 79.2%). mp, 152–154 °C (lit.¹⁰ 154–155 °C); MS (+ESI) m/z 166.96 [M+H]⁺.

Synthesis of 2-Chloromethyl-1-methyl-benzimidazole (2) by Conventional Method. To a solution of compound 1 (1.01 g, 6.07 mmol) in anhydrous toluene (10 mL), dimethyl sulfate (0.63 mL, 6.67 mmol) was added dropwise at room temperature. The reaction mixture was

refluxed in oil bath for 3 h. After cooling, water (10 mL) was added and the mixture was basified with ammonia.¹¹ After filtration, the solution was extracted with CHCl₃ (3 × 20 mL). The organic layer was dried over anhydrous Na₂SO₄ and concentrated. Purification by CC on silica gel eluting with PE–acetone (4:1) gave the major product **2** as a light yellow solid (0.55 g, yield 50%) and the minor product **3** as a white crystal (0.29 g, yield 9%). Compound **2**: HR-MS (ESI): *m*/*z* calcd. for C₉H₉ClN₂: 181.0527; found: 181.0514 [M+H]⁺; Compound **3**: mp, 126 – 128 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.24 (d, *J* = 7.5 Hz, 1H, ArH), 6.99 (d, *J* = 7.8 Hz, 1H, ArH), 6.67 (t, *J* = 6.7 Hz, 2H, ArH), 4.23 (d, *J* = 3.2 Hz, 1H, -NH–), 3.84 (q, *J* = 13.7 Hz, 2H, -CH₂Cl–), 3.18 (s, 3H, -NMe–H), 2.85 (d, *J* = 4.8 Hz, 3H, -HNMe–H); ¹³C NMR (125 MHz, CDCl₃) δ 167.7 (-C==O), 145.0 (-C–NH–), 130.4 (ArC), 128.0 (ArC), 127.0 (ArC), 117.1 (ArC), 111.3 (ArC), 42.3 (-CH₂Cl–), 36.1 (-NMe–C), 30.2 (-HNMe–C); HR-MS (ESI): *m*/*z* calcd. for C₁₀H₁₃ClN₂O: 213.0789; found: 213.0765 [M+H]⁺.

Synthesis of 2-Chloromethyl-1-methyl-5-nitro-1H-benzimidazole (6) by Conventional Method. A mixture of 4-nitro-2-amino-1-*N*-methylaniline (3.52 g, 21 mmol) and chloroacetic acid (2.58 g, 25.2 mmol) was refluxed for 4 h in 45 mL of 4 N HCl and then cooled to room temperature and adjusted to pH = 7 with ammonia. A gray residue was obtained.^{13–15} Purification by column chromatography on neutral Al₂O₃ eluting with CHCl₃–MeOH (100:0.8) gave compound 6 as a yellow solid (3.37 g, yield 71%), mp, 180–182 °C (lit.¹³ 191–192 °C). ¹H NMR (500 MHz, CDCl₃) δ 8.66 (s, 1H, ArH), 8.28 (d, *J* = 8.9 Hz, 1H, ArH), 7.44 (d, *J* = 8.9 Hz, 1H, ArH), 4.87 (s, 2H, –CH₂O–), 3.96 (s, 3H, Me–H); ¹³C NMR (125 MHz, CDCl₃) δ

152.9 (ArC), 144.2 (ArC), 141.4 (-N-C=N-), 140.2 (ArC), 119.5 (ArC), 117.2 (ArC), 109.8 (ArC), 36.5 ($-CH_2Cl-$), 31.0 (Me-C). HR-MS (ESI): m/z calcd. for C₉H₈ClN₃O₂: 226.0378; found: 226.0352 [M+H]⁺.

General Procedure To Synthesize Compounds 4a–q by Conventional Method. To a solution of compound 2 (90.25 mg, 0.5 mmol) and different phenols (0.55 mmol) in dry acetone (30 mL), anhydrous potassium carbonate (103.5 mg, 0.75 mmol) was added. The mixture was refluxed in oil bath at 60 °C for 8 h. After cooling and filtration, the solution was concentrated under vacuum and then purified by CC on silica gel eluting with CHCl₃–MeOH (9:1–95:5) to obtain the title compounds 4a-q.

1-(3-((1-Methyl-1Ĥ-benzo[d]imidazol-2-yl)methoxy)phenyl)ethanone (**4a**). Yield, 81%; white solid; mp, 128–130 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.82–7.75 (m, 1H, ArH), 7.70–7.64 (m, 1H, ArH), 7.57 (d, J = 7.6 Hz, 1H, ArH), 7.41–7.34 (m, 2H, ArH × 2), 7.30 (dq, J = 7.0, 5.4 Hz, 3H, ArH × 3), 5.42 (s, 2H, $-CH_2O-$), 3.88 (s, 3H, Me-H), 2.58 (s, 3H, Me-H). ¹³C NMR (100 MHz, CDCl₃) δ 197.9 (-C=O), 158.2 (ArC), 149.0 (ArC), 142.3 (ArC), 138.8 (-N=C-), 136.3 (ArC), 130.0 (ArC), 123.5 (ArC), 122.6 (ArC), 122.0 (ArC), 120.3 (ArC), 119.9 (ArC), 114.3 (ArC), 109.6 (ArC), 63.5 ($-CH_2O-$), 30.4 (-NMe-C), 26.9 (-Me-C). HR-MS (ESI): *m*/*z* calcd. for C₁₇H₁₆N₂O₂: 281.1285; found: 281.1264 [M+H]⁺.

1-(2-((1-Methyl-1H-benzo[d]imidazol-2-yl)methoxy)phenyl)ethanone (**4b**). Yield, 83%; white solid; mp, 122–124 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.79 (dd, *J* = 6.9, 1.3 Hz, 1H, ArH), 7.68 (dd, *J* = 7.7, 1.8 Hz, 1H, ArH), 7.46 (ddd, *J* = 8.6, 7.4, 1.8 Hz, 1H, ArH), 7.40– 7.36 (m, 1H, ArH), 7.36–7.28 (m, 3H, ArH × 3), 7.08–6.99 (m, 1H, ArH), 5.48 (s, 2H, –CH₂O–), 3.90 (s, 3H, Me–H), 2.55 (s, 3H, Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 199.6 (–C=O), 156.9 (ArC), 148.8 (ArC), 142.1 (–N=C–), 136.3 (ArC), 133.8 (ArC), 130.5 (ArC), 129.0 (ArC), 123.7 (ArC), 122.7 (ArC), 121.8 (ArC), 120.3 (ArC), 113.3 (ArC), 109.7 (ArC), 63.8 (–CH₂O–), 31.8 (–NMe–C), 30.5 (Me–C). HR-MS (ESI): *m/z* calcd. for C₁₇H₁₆N₂O₂: 281.1285; found: 281.1266 [M+H]⁺.

1-(4-((1-Methyl-1H-benzo[d]imidazol-2-yl)methoxy)phenyl)ethanone (4c). Yield, 86%; white solid; mp, 186–188 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.00–7.86 (m, 2H), 7.78 (dd, *J* = 6.8, 1.5 Hz, 1H, ArH), 7.38–7.27 (m, 3H, ArH × 3), 7.19–7.08 (m, 2H, ArH × 2), 5.44 (s, 2H, $-CH_2O-$), 3.87 (s, 3H, Me–H), 2.53 (s, 3H, Me–H); ¹³C NMR (100 MHz, CDCl₃) δ 196.8 (-C=O), 161.7 (ArC), 148.8 (ArC), 142.3 (-N=C-), 136.3 (ArC), 131.3 (ArC), 130.8 (ArC × 2), 123.6 (ArC), 122.6 (Ph- C), 120.3 (ArC), 114.7 (ArC × 2), 109.6 (ArC), 63.5 ($-CH_2O-$), 30.4 (-NMe-C), 26.5 (Me–C). HR-MS (ESI): *m*/*z* calcd. for C₁₇H₁₆N₂O₂: 281.1285; found: 281.1265 [M+H]⁺.

Propyl 4-((1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)benzoate (4d). Yield, 80%; white solid; mp, 96–98 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.10–7.92 (m, 2H, ArH × 2), 7.82–7.75 (m, 1H, ArH), 7.42–7.24 (m, 3H, ArH × 3), 7.20–7.04 (m, 2H, ArH × 2), 5.44 (s, 2H, –CH₂O–), 4.23 (t, J = 6.7 Hz, 2H, –CH₂O–), 3.88 (s, 3H, Me-H), 1.85–1.68 (m, 2H, –CH₂–), 1.00 (t, J = 7.4 Hz, 3H, Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 166.3 (ArC), 161.5 (ArC), 148.8 (ArC), 142.2 (ArC), 136.3 (ArC), 131.8 (ArC × 2), 124.2 (ArC), 123.6 (ArC), 122.6 (ArC), 120.3 (ArC), 114.6 (ArC × 2), 109.6 (ArC), 66.5 (–CH₂O–), 63.5 (–CH₂O–), 30.5 (–NMe–C), 22.3 (–CH₂–), 10.6 (Me-C). HR-MS (ESI): m/z calcd. for C₉H₉ClN₂: 325.1547; found: 325.1526 [M+H]⁺.

2-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-1-methyl-1H-benzo[d]imidazole (4n). Yield, 80%; light pink solid; mp, 138–140 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.77 (dd, *J* = 6.9, 1.5 Hz, 1H, ArH), 7.32 (dtd, *J* = 9.2, 7.1, 1.5 Hz, 3H, ArH × 3), 6.69 (d, *J* = 8.5 Hz, 1H), 6.62 (d, *J* = 2.5 Hz, 1H, ArH), 6.51 (dd, *J* = 8.5, 2.5 Hz, 1H, ArH), 5.90 (s, 2H, $-OCH_2O-$), 5.30 (d, *J* = 1.8 Hz, 2H, $-CH_2O-$), 3.87 (d, *J* = 2.1 Hz, 3H, -Me-H-). ¹³C NMR (100 MHz, CDCl₃) δ 152.4 (ArC), 148.5 (ArC), 147.5 (ArC), 141.6 (ArC), 141.3 (-C-), 135.3 (ArC), 122.4 (ArC), 121.5 (ArC), 119.2 (ArC), 108.5 (ArC), 107.2 (ArC), 105.3 (ArC), 100.4 (ArC), 97.6 ($-OCH_2O-$), 63.5 ($-CH_2O-$), 29.4 (-NMe-C). HR-MS (ESI): *m*/*z* calcd. for C₁₆H₁₄N₂O₃: 283.1077; found: 283.1059 [M+H]⁺.

3-Methoxy-4-((1-methyl-1H-benzo[d]imidazol-2-yl)methoxy)benzaldehyde (40). Yield, 88%; light yellow solid; mp, 144 – 146 °C; ¹H NMR (400 MHz, CDCl₃) δ 9.83 (s, 1H, ArH), 7.77 (dd, J = 6.9, 1.4 Hz, 1H, ArH), 7.40 (dd, J = 5.6, 1.7 Hz, 2H, ArH × 2), 7.36 (d, J = 8.7 Hz, 2H, ArH × 2), 7.34 – 7.26 (m, 2H, ArH × 2), 5.54 (s, 2H, –CH₂O–), 3.92 (s, 3H, –OMe–H–), 3.91 (s, 3H, –Me–H–). ¹³C NMR (100 MHz, CDCl₃) δ 191.0 (–CHO), 152.7 (ArC), 150.3 (ArC), 148.6 (ArC), 142.2 (ArC), 136.4 (ArC), 131.2 (ArC), 126.8 (ArC), 123.6 (ArC), 122.6 (ArC), 120.3 (ArC), 113.4 (ArC), 109.6 (ArC), 109.4 (ArC), 64.5 (–CH₂O–), 56.1 (–OMe–C), 30.5 (–NMe–C). HR-MS (ESI): m/z calcd. for C₁₇H₁₆N₂O₃: 297.1234; found: 297.1220 [M+H]⁺.

General Synthetic Procedure for Compounds 5a–c by a Slightly Modified Method. To a solution of compound 1 (166.5 mg, 1 mmol) and triethylamine (0.13, 0.9 mmol) in dry acetone (10 mL), three different acyl chlorides including acetyl chloride, methanesulfonyl chloride and 4-chlorobenzenesulfonyl chloride (0.9 mmol) was added dropwise. The mixture was stirred at 0 °C for 12 h.^{16–18} The mixture was concentrated under vacuum and then purified by CC on silica gel eluting with PE–EtOAc (3:1–5:1) to obtain the corresponding compounds Sa–c.

2-(Chloromethyl)-1-((4-chlorophenyl)sulfonyl)-1H-benzo[d]imidazole (5c). Yield, 68%; white solid; mp, 150–152 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.09–8.01 (m, 2H, ArH × 2), 7.92 (t, *J* = 5.5 Hz, 1H, ArH), 7.78–7.73 (m, 1H, ArH), 7.50 (dd, *J* = 9.1, 2.1 Hz, 2H, ArH × 2), 7.45–7.37 (m, 2H, ArH × 2), 5.16 (s, 2H, -CH₂–). ¹³C NMR (100 MHz, CDCl₃) δ 149.0 (C), 142.0 (ArC), 141.7 (ArC), 136.2, 132.9 (ArC), 130.1 (ArC × 2), 129.1 (ArC × 2), 126.5 (ArC), 125.6 (ArC), 121.3 (ArC), 113.6 (ArC), 37.9 (-CH₂–). HR-MS (ESI): *m*/*z* calcd. for C₁₄H₁₀Cl₂N₂O₂S: 340.9913; found: 340.9904 [M+H]⁺.

General Procedure To Synthesize Compounds 7a-n by Conventional Method. The method to synthesize this series of compounds is the same as the compound 4.

1-(3-((1-Methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)phenyl)ethanone (**7a**). Yield, 82%; white solid; mp, 200–202 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.62 (d, J = 2.0 Hz, 1H, ArH), 8.19 (dd, J = 8.9, 2.1 Hz, 1H, ArH), 7.60 (s, 1H, ArH), 7.53 (d, J = 7.7 Hz, 1H, ArH), 7.41 – 7.31 (m, 2H, ArH × 2), 7.22 (dd, J = 8.2, 2.6 Hz, 1H, ArH), 5.39 (s, 2H, –CH₂O–), 3.90 (s, 3H, Me-H), 2.53(s, 3H, Me). ¹³C NMR (100 MHz, CDCl₃) δ 197.7 (–C=O), 158.0 (ArC), 153.0 (ArC), 144.0 (ArC), 141.6 (–N=C–), 140.3 (ArC), 138.9 (ArC), 130.2 (ArC), 122.5 (ArC), 119.9 (ArC), 119.3 (ArC), 117.1 (ArC), 114.0 (ArC), 109.7 (ArC), 63.4 (–CH₂O–), 31.0 (–NMe–C), 26.9 (–O=C–Me–C). HR-MS (ESI): m/z calcd. for C₁₇H₁₅N₃O₄: 326.1135; found: 326.1126 [M+H]⁺.

1-(2-((1-Methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)phenyl)ethanone (**7b**). Yield, 81%; white solid; mp, 202–204 °C; ¹H NMR (400 MHz, Pyr) δ 8.89 (d, J = 2.1 Hz, 1H, ArH), 8.30 (dd, J =9.0, 2.2 Hz, 1H, ArH), 7.88 (dd, J = 7.7, 1.7 Hz, 1H, ArH), 7.52 (dd, J = 8.3, 3.4 Hz, 2H, ArH × 2), 7.50 – 7.44 (m, 1H, 1H, ArH), 7.09 – 7.02 (m, 1H, 1H, ArH), 5.70 (s, 2H, –CH₂O–), 3.88 (s, 3H, Me–H), 2.62 (s, 3H, Me–H). ¹³C NMR (100 MHz, C₅D₅N) δ 198.8 (–C= O), 157.2 (ArC), 153.6 (ArC), 143.9 (ArC), 141.9 (–N=C–), 140.7 (ArC), 133.7 (ArC), 130.5 (ArC), 129.3 (ArC), 121.8 (ArC), 118.8 (ArC), 116.8 (ArC), 113.8 (ArC), 110.6 (ArC), 63.5 (–CH₂O–), 31.6 (–NMe–C), 30.6 (–O=C–Me–C). HR-MS (ESI): m/z calcd. for C₁₇H₁₅N₃O₅: 326.1135; found: 326.1128 [M+H]⁺.

1-(4-((1-Methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)phenyl)ethanone (**7c**). Yield, 85%; white solid; mp, 254–256 °C; ¹H NMR (400 MHz, C₃D₃N) δ 8.92 (d, *J* = 2.2 Hz, 1H, ArH), 8.31 (dd, *J* = 8.9, 2.2 Hz, 1H, ArH), 8.09 (d, *J* = 8.9 Hz, 2H, ArH × 2), 7.50 (d, *J* = 9.0 Hz, 1H, ArH), 7.34 (d, *J* = 8.9 Hz, 2H, ArH × 2), 5.69 (s, 2H, -CH₂O-), 3.81 (s, 3H, Me-H), 2.51 (s, 3H, Me-H). HR-MS (ESI): m/z calcd. for C₁₇H₁₅N₃O₆: 326.1135; found: 326.1128 [M+H]⁺.

Propyl-4-((1-methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)benzoate (**7d**). Yield, 83%; white solid; mp, 140–142 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 2.1 Hz, 1H, ArH), 8.25 (dd, *J* = 9.0, 2.1 Hz, 1H,ArH), 8.05–7.98 (m, 2H, ArH × 2), 7.43 (d, *J* = 9.0 Hz, 1H, ArH), 7.14–7.06 (m, 2H, ArH × 2), 5.47 (s, 2H, $-CH_2O-$), 4.24 (t, *J* = 6.7 Hz, 2H, $-OCH_2Et$), 3.96 (s, 3H, Me–H), 1.76 (dq, *J* = 14.2, 7.2 Hz, 2H, $-CH_2Me$), 1.00 (t, *J* = 7.4 Hz, 3H, Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 166.2 (-C=O), 161.2 (ArC), 152.7 (ArC), 144.1 (ArC), 141.6 (-N=C-), 140.3 (ArC), 131.9 (ArC × 2), 124.6 (ArC), 119.3 (ArC), 117.1 (ArC), 114.5 (ArC × 2), 109.7 (ArC), 66.6 ($-CH_2O-$), 63.3 ($-CH_2Et$), 31.1 (-NMe-C), 22.2 ($-CH_2Me$), 10.6 (Me-C). HR-MS (ESI): m/z calcd. for $C_{19}H_{19}N_3O_5$: 370.1397; found: 370.1384 [M+H]⁺.

2-((4-Fluorophenoxy)methyl)-1-methyl-5-nitro-1H-benzo[d]imidazole (**7e**). Yield, 80%; light yellow solid; mp, 224–226 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.69 (d, *J* = 2.1 Hz, 1H,ArH), 8.27 (dd, *J* = 8.9, 2.1 Hz, 1H, ArH), 7.43 (d, *J* = 9.0 Hz, 1H, ArH), 7.07–6.93 (m, 4H, ArH × 4), 5.38 (s, 2H, –CH₂O–), 3.96 (s, 3H, Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 159.3 (ArC), 153.8 (ArC), 153.2 (ArC), 144.1 (ArC), 141.60 (–N=C–), 140.4 (ArC), 119.3 (ArC), 117.1 (ArC), 116.5 (ArC), 116.3 (ArC), 116.1 (ArC), 116.1 (ArC), 109.6 (ArC), 64.0 (–CH₂O–), 31.1 (–NMe–C). HR-MS (ESI): *m/z* calcd. for C₁₅H₁₂FN₃O₃: 302.0935; found: 302.0925 [M+H]⁺.

2-((4-Chlorophenoxy)methyl)-1-methyl-5-nitro-1H-benzo[d]imidazole (**7f**). Yield, 81%; white solid; mp, 256–258 °C; ¹H NMR (400 MHz, C₅D₅N) δ 8.90 (d, *J* = 2.1 Hz, 1H, ArH), 8.30 (dd, *J* = 8.9, 2.2 Hz, 1H, ArH), 7.48 (d, *J* = 9.0 Hz, 1H, ArH), 7.41–7.32 (m, 2H, ArH × 2), 7.24–7.21 (m, 2H, ArH × 2), 5.56 (s, 2H, –CH₂O–), 3.78 (s, 3H, Me–H). HR-MS (ESI): *m*/*z* calcd. for C₁₅H₁₂ClN₃O₃: 318.0640; found: 318.0633 [M+H]⁺.

4-((1-Methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)benzaldehyde (**7g**). Yield, 83%; white solid; mp, 248–250 °C; ¹H NMR (400 MHz, C₅D₅N) δ 10.02 (s, 1H, –CHO), 8.92 (d, *J* = 2.1 Hz, 1H, ArH), 8.31 (dd, *J* = 9.0, 2.2 Hz, 1H, ArH), 7.96 (d, *J* = 8.8 Hz, 2H, ArH × 2), 7.50 (d, *J* = 9.0 Hz, 1H, ArH), 7.38 (d, *J* = 8.7 Hz, 2H, ArH × 2), 5.70 (s, 2H, –CH₂O–), 3.81 (s, 3H, Me-H). HR-MS (ESI): m/z calcd. for C₁₆H₁₃N₃O₄: 312.0979; found: 312.0968 [M+H]⁺.

2-((4-Allyl-2-methoxyphenoxy)methyl)-1-methyl-5-nitro-1Hbenzo[d] imidazole (**7h**). Yield, 83%; light yellow solid; mp, 114–116 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, J = 2.1 Hz, 1H, ArH), 8.24 (dd, J = 8.9, 2.1 Hz, 1H, ArH), 7.41 (d, J = 9.0 Hz, 1H, ArH), 7.03 (d, J = 8.1 Hz, 1H, ArH), 6.77–6.67 (m, 2H, ArH × 2), 5.93 (ddt, J = 16.9, 10.1, 6.7 Hz, 1H, $-CH_2CH-$), 5.41 (s, 2H, $-CH_2O-$), 5.15 – 5.01 (m, 2H, $-=CH_2$), 4.02 (s, 3H, MeO-H), 3.84 (s, 3H, Me–H), 3.32 (d, J = 6.7 Hz, 2H, $-CH_2CH-$). ¹³C NMR (100 MHz, CDCl₃) δ 153.8 (ArC), 150.1 (ArC), 145.3 (ArC), 143.9 (ArC), 141.6 (-N=C-), 140.5 (ArC), 137.4 (ArC), 135.5 (ArC), 120.8 (ArC), 119.1 (ArC), 117.00 (ArC), 116.1 ($=CH_2$), 115.9 (ArC), 112.6 (ArC), 109.5 (ArC), 65.2 ($-CH_2O-$), 55.9 (MeO-C), 40.0 ($-CH_2-$), 31.0 (-NMe-C). HR-MS (ESI): m/z calcd. for C₁₉H₁₉N₃O₄: 354.1448; found: 354.1436 [M+H]⁺.

1-Methyl-2-((naphthalen-1-yloxy)methyl)-5-nitro-1H-benzo[d]imidazole (**7i**). Yield, 82%; pink solid; mp, 200–202 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.78 – 8.67 (m, 1H, ArH), 8.34 – 8.17 (m, 2H, ArH × 2), 7.82 (d, *J* = 7.7 Hz, 1H, ArH), 7.63–7.46 (m, 3H, ArH × 3), 7.40 (dd, *J* = 18.9, 8.6 Hz, 2H, ArH × 2), 7.11 (d, *J* = 7.6 Hz, 1H, ArH), 5.62 (s, 2H, $-CH_2O-$), 4.00 (s, 3H, Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 153.4 (ArC), 153.3 (ArC), 144.0 (ArC), 141.7 (-N=C-), 140.5 (ArC), 134.7 (ArC), 127.9 (ArC), 126.8 (ArC), 125.9 (ArC), 125.9 (ArC), 125.4 (ArC), 121.9 (ArC), 121.5 (ArC), 119.2 (ArC), 117.1 (ArC), 109.6 (ArC), 105.6 (ArC), 63.5 ($-CH_2O-$), 31.2 (-NMe-C). HR-MS (ESI): *m/z* calcd. for C₁₉H₁₅N₃O₃: 334.1186; found: 334.1177 [M+H]⁺.

Ethyl 4-((1-methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)benzoate (**7***j*). Yield, 83%; white solid; mp, 190–192 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 2.0 Hz, 1H, ArH), 8.26 (dd, *J* = 8.9, 2.1 Hz, 1H, ArH), 8.01 (d, *J* = 8.8 Hz, 2H, ArH × 2), 7.43 (d, *J* = 9.0 Hz, 1H, ArH), 7.10 (d, *J* = 8.9 Hz, 2H, ArH × 2), 7.43 (d, *J* = 9.0 Hz, 1H, ArH), 7.10 (d, *J* = 8.9 Hz, 2H, ArH × 2), 5.47 (s, 2H, $-CH_2O-$), 4.34 (q, *J* = 7.1 Hz, 2H, $-OCH_2CH_3-$), 3.96 (s, 3H, Me– H), 1.36 (t, *J* = 7.1 Hz, 3H,Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 166.2 (ArC), 161.2 (ArC), 152.7 (ArC), 144.1 (ArC), 141.56 (-N=C–), 140.3 (ArC), 131.9 (ArC × 2), 124.6 (ArC), 119.3 (ArC), 117.1 (ArC), 114.5 (ArC × 2), 109.7 (ArC), 63.3 ($-CH_2O-$), 61.0 ($-OCH_2Me$), 31.1 (-NMe-C), 14.48 (Me–C). HR-MS (ESI): *m/z* calcd. for C₁₈H₁₇N₃O₅: 356.1241; found: 356.1231 [M+H]⁺.

Methyl 4-((1-methyl-5-nitro-1H-benzo[d]imidazol-2-yl)methoxy)benzoate (**7k**). Yield, 81%; white solid; mp, 246–248 °C; ¹H NMR (400 MHz, C₅D₅N) δ 8.94–8.89 (m, 1H, ArH), 8.30 (dd, J = 8.9, 2.2 Hz, 1H, ArH), 8.24–8.12 (m, 2H, ArH \times 2), 7.49 (d, J = 9.0 Hz, 1H, ArH), 7.42–7.30 (m, 2H, ArH \times 2), 5.67 (s, 2H, $-\rm CH_2O-$), 3.80 (s, 6H, Me \times 2-H). HR-MS (ESI): m/z calcd. for $\rm C_{17}H_{15}N_3O_5$: 342.1084; found: 342.1079 $\rm [M+H]^+.$

2-((4-(tert-Butyl)phenoxy)methyl)-1-methyl-5-nitro-1H-benzo-[d]imidazole (**7l**). Yield, 85%; yellow solid; mp, 158–160 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.69 (d, J = 2.0 Hz, 1H, ArH), 8.25 (dd, J = 8.9, 2.1 Hz, 1H, ArH), 7.42 (d, J = 9.0 Hz, 1H, ArH), 7.39–7.27 (m, 2H, ArH × 2), 7.06–6.97 (m, 2H, ArH × 2), 5.40 (s, 2H, -CH₂O–), 3.99 – 3.93 (m, 3H, Me–H), 1.29 (s, 9H, Me × 3-H). ¹³C NMR (100 MHz, CDCl₃) δ 155.4 (ArC), 153.7 (ArC), 145.0 (ArC), 144.0 (ArC), 141.5 (-N=C-), 140.4 (ArC), 126.7 (ArC 2), 119.2 (ArC), 117.0 (ArC), 114.3 (ArC × 2), 109.6 (ArC), 71.0 (-CH₂O–), 34.3 (-C-Me₃), 31.6 (Me × 3-C), 31.1 (-NMe–C). HR-MS (ESI): *m*/*z* calcd. for C₁₇H₁₅N₃O₅: 340.1656; found: 340.1642 [M+H]⁺.

1-Methyl-5-nitro-2-(phenoxymethyl)-1H-benzo[d]imidazole (**7m**). Yield, 82%; light yellow solid; mp, 234–236 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.70 (d, J = 2.1 Hz, 1H, ArH), 8.27 (dd, J = 9.0, 2.1 Hz, 1H, ArH), 7.43 (d, J = 9.0 Hz, 1H, ArH), 7.32 (dd, J = 8.5, 7.5 Hz, 2H, ArH × 2), 7.07 (d, J = 8.0 Hz, 2H, ArH × 2), 7.02 (t, J = 7.4 Hz, 1H, ArH), 5.42 (s, 2H, $-CH_2O-$), 3.97 (s, 3H, Me–H). ¹³C NMR (100 MHz, CDCl₃) δ 157.6 (ArC), 153.3 (ArC), 143.9 (ArC), 141.5 (-N=C-), 140.3 (ArC), 129.8 (ArC × 2), 122.1 (ArC), 119.1 (ArC), 116.9 (ArC), 114.7 (ArC × 2), 109.5 (ArC), 63.2 ($-CH_2O-$), 31.0 (-NMe-C). HR-MS (ESI): m/z calcd. for $C_{15}H_{13}N_3O_3$: 284.1030; found: 284.1016 [M+H]⁺.

2-((Benzo[d][1,3]dioxol-5-yloxy)methyl)-1-methyl-5-nitro-1Hbenzo[d]imidazole (**7n**). Yield, 81%; light yellow solid; mp, 246–248 °C; ¹H NMR (400 MHz, C₅D₅N) δ 8.88 (d, *J* = 2.1 Hz, 1H, ArH), 8.29 (dd, *J* = 8.9, 2.2 Hz, 1H, ArH), 7.47 (d, *J* = 8.9 Hz, 1H, ArH), 6.98 (d, *J* = 2.5 Hz, 1H, ArH), 6.86 (d, *J* = 8.5 Hz, 1H, ArH), 6.74 (dd, *J* = 8.5, 2.5 Hz, 1H, ArH), 5.94 (s, 2H, $-OCH_2O-$), 5.52 (s, 2H, CH₂O), 3.80 (s, 3H, Me-H). HR-MS (ESI): *m*/*z* calcd. for C₁₆H₁₃N₃O₅: 328.0928; found: 328.0921 [M+H]⁺.

For spectral data of known compounds 1, 2, 4e-m, 4p-q, 5a-b, and 6 see the Supporting Information.

Antifungal Bioassay. According to our previously reported methods,^{10,19–21} fungicidal activities of the synthetic compounds were tested in vitro against five plant pathogenic fungi (*Cytospora* sp., *Colletotrichum gloeosporioides, Botrytis cinerea, Alternaria solani*, and *Fusarium solani*) by using the mycelium growth rate method. All of the fungi were provided by the Institute of Pesticides, Northwest A&F University. The strains were retrieved from the storage tube and cultured for 2 weeks at 28 °C on potato dextrose agar (PDA).

Antifungal activity was assessed as follows: the synthesized compounds were screened in vitro for their antifungal activities against the five phytopathogenic fungi. PDA medium was prepared in the flasks and sterilized. Those compounds were dissolved in acetone before mixing with molten agar at 55 °C, and final concentrations of the stock solutions of the tested compounds dissolved in acetone were 100, 50, 25, 12.5, and $6.25 \,\mu g/mL$. The medium was then poured into sterilized Petri dishes. All types of fungi were incubated in PDA at 28 °C for 1 week to get new mycelium for the antifungal assays, and a mycelia disk of approximately 4 mm diameter cut from culture medium was picked up with a sterilized inoculation needle and inoculated in the center of the PDA Petri dishes.^{5,14} The inoculated Petri dishes were incubated at 28 °C for 3–4 d. Acetone was served as the control, while commercially available agricultural fungicide hymexazol was used as a positive control. Each sample was measured by three replicate, each colony diameter of the three replicate was measured 4 times by cross bracketing method. After the mycelia grew completely, the diameters of the mycelia were measured and the inhibition rate was calculated according to the formula

inhibition rate (%) = $(C - T)/(C - 4mm) \times 100\%$

where *C* is the average diameter of mycelia in the blank test, and *T* is the average diameter of mycelia on treated PDA with those compounds. The inhibition ratio of those compounds at the concentration of 100 μ g/mL is summarized in Table 1. The IC₅₀ (median inhibitory concentration) values of some compounds were determined, and the results were listed in Table 2.

Table 1. Preliminary Antifungal Activities of Compounds at 100 μ g/mL^{*a*}

| compound | average values of inhibition rate (%) to five pathogens | | | | | |
|--------------|---|------------|---------------|------------|-------------|--|
| compound | C. s. | C. g. | В. с. | A. s. | F. s. | |
| 1 | <5.00 | 67.57 | 53.22 | 25.29 | 6.59 | |
| 2 | 45.40 | 69.57 | 91.53 | 51.56 | 28.76 | |
| 3 | <5.00 | 41.27 | 64.39 | 25.29 | 30.11 | |
| 4a | 55.46 | 41.27 | 82.46 | 64.52 | 78.49 | |
| 4b | 64.52 | 71.43 | 64.91 | 65.52 | 64.73 | |
| 4c | 87.07 | 38.10 | 65.41 | 55.67 | 81.85 | |
| 4d | 48.28 | 20.63 | <5.00 | 63.62 | 42.20 | |
| 4e | 80.60 | 62.67 | 47.37 | 85.22 | 83.87 | |
| 4f | 76.29 | 90.48 | 83.05 | 77.83 | 64.07 | |
| 4g | 20.98 | 49.21 | <5.00 | 27.75 | 11.96 | |
| 4h | 49.71 | 38.10 | 47.37 | 40.07 | 60.35 | |
| 4i | 62.64 | 22.22 | <5.00 | 50.74 | 52.96 | |
| 4j | 79.89 | 71.74 | 35.90 | 39.08 | 21.37 | |
| 4k | 31.03 | <5.00 | 6.43 | 64.62 | 48.25 | |
| 41 | 28.16 | 63.84 | 64.81 | 23.65 | <5.00 | |
| 4m | 84.20 | 87.30 | 29.82 | 75.37 | 84.54 | |
| 4n | 80.60 | 80.95 | 88.30 | 63.98 | 74.46 | |
| 4o | 10.20 | <5.00 | 15.20 | 40.89 | 24.73 | |
| 4p | 26.01 | 14.29 | 59.06 | 17.90 | <5.00 | |
| 4q | 19.54 | 41.27 | <5.00 | 11.33 | 8.60 | |
| 5a | 8.05 | 43.87 | 57.26 | 11.33 | 21.37 | |
| 5b | 100.00 | 100.00 | 79.86 | 67.98 | 79.17 | |
| 5c | 27.44 | 74.60 | 57.26 | 31.86 | 28.09 | |
| 6 | 100.00 | 100.00 | 48.70 | 100.00 | 100.00 | |
| 7a | 51.87 | <5.00 | <5.00 | <5.00 | <5.00 | |
| 7b | <5.00 | <5.00 | <5.00 | 13.79 | <5.00 | |
| 7c | <5.00 | <5.00 | 38.60 | 33.50 | <5.00 | |
| 7d | 10.92 | <5.00 | <5.00 | 8.05 | 19.35 | |
| 7e | 22.41 | <5.00 | <5.00 | <5.00 | 9.95 | |
| 7f | 10.20 | 6.35 | 100.00 | 30.21 | <5.00 | |
| 7g | 9.48 | <5.00 | <5.00 | 16.26 | <5.00 | |
| 7h | <5.00 | <5.00 | 23.98 | 35.14 | 25.40 | |
| 7i | <5.00 | <5.00 | <5.00 | 19.54 | <5.00 | |
| 7j | <5.00 | <5.00 | <5.00 | 11.33 | <5.00 | |
| 7k | <5.00 | 59.13 | 32.20 | <5.00 | 18.01 | |
| 71 | <5.00 | 30.16 | 57.26 | 30.21 | <5.00 | |
| 7m | <5.00 | <5.00 | 7.89 | 10.51 | 5.91 | |
| 7n | 12.36 | <5.00 | 91.23 | 7.22 | 34.81 | |
| Hy | 38.94 | 49.21 | 100.00 | 80.30 | 72.45 | |
| A.s., Altern | aria solani: | B.c., Botr | vtis cinerea: | C.g., Coli | letotrichum | |

"A.s., Alternaria solani; B.c., Botrytis cinerea; C.g., Colletotrichum gloeosporioides; C.s. Cytospora sp; F.s., Fusarium solani; Hy, hymexazol.

The data of the fungicidal activities were statistically analyzed using Excel software from Windows to give the results of IC_{50} values. The results were expressed as the mean \pm SD of triplicate experiments

RESULTS AND DISCUSSION

Chemistry. The synthetic routes of the title compounds are outlined in Scheme 1. Reaction of *o*-phenylenediamine with chloroacetic acid under reflux gave compound 1 in 79% yield, which was then treated with dimethyl sulfate in dried toluene to introduce a methyl group at N-1 position, affording the corresponding benzimidazole 2 as a major product in 50% yield and 2-chloro-N-(2-(methylamino)phenyl)acetamide 3 as a minor one. A possible formation mechanism of 3 was shown in Scheme 2. A formation of benzimidazole was thought to be reversible,²² so a primary amine group of the resulting amide intermediate proceeds a first nucelophilic substitution reaction with dimethyl sulfate followed

by a second nucelophilic substitution to form **3**. Subsequent Williamson reaction of the resulting intermediate **2** with various substituted phenols in dry acetone in anhydrous K_2CO_3 produced the desired compounds $4\mathbf{a}-\mathbf{q}$ in good yields (>80%). Furthermore, treatment of **1** in the presence of triethylamine with three acetyl chloride and two sulfonyl chlorides yielded the corresponding products $5\mathbf{a}-\mathbf{c}$ in ca. 70% yield. Similarly, the target compounds $7\mathbf{a}-\mathbf{n}$ were prepared from **6** in good yields (>80%). At the beginning of this study, we made attempts to prepare **6** from **2** through nitration reaction, but an inseparable mixture of two isomers, **6** and its 6-nitro-1*H*-benzimidazole, was obtained by column chromatography.

The structures of the synthetic compounds were confirmed by ¹H NMR, ¹³C NMR and MS, as well as HRESIMS spectroscopic data. Out of the 35 synthesized derivatives, 22 compounds (3, 4a–d, 4n, 4o, 5c, and 7a–n) were new. It should be noted that the synthetic approach for this family of compounds used in the current study is a simple, efficient and low-cost method with high yields.

Antifungal Activity. Preliminary in vitro screening results of the title compounds for antifungal activities against five phytopathogenic fungi, *Cytospora* sp., *Colletotrichum gloeosporioides, Botrytis cinerea, Alternaria solani,* and *Fusarium solani,* are listed in Table 1. The results indicated that some of these synthetic compounds exhibited over 65% growth inhibition against mycelial growth of these tested fungi at concentrations of 100 μ g/mL. Here, the inhibition rates were for only IC₅₀ values for further comparison.

Encouraged by these preliminary findings, we planned further SAR studies on the title compounds. We determined their IC₅₀ (median inhibitory concentration) values by using mycelial growth inhibitory rate method. As shown in Table 2, the tested compounds presented different fungicidal activity against Cytospora sp. and C. gloeosporioides, superior to the positive control hymexazol (IC₅₀ > 100 μ g/mL), whereas they were inactive or less active than hymexazol against B. cinerea and A. solani (IC₅₀ = 8.92 and 14.03 μ g/mL, respectively). Specifically, a fungicidal activity of the intermediate 6, bearing a $-NO_2$ group, was 2–3 fold of 1 and 2 against the five fungal species (except B. cinerea). Notably, 6 showed remarkable antifungal activities against Cytospora sp., C. gloeosporioides, A. *solani*, and *F. solani* (IC₅₀ = 22.48, 28.03, 27.95, and 23.34 μ g/mL, respectively). The results revealed that the presence of the NO₂ group at the 5-position of benzimidazole ring in 6 could be critical for antifungal activity.

In case of the 4-series, compound 4m, with nonsubstituents in the benzene ring displaying increased effects, showed higher growth inhibition of the three fungi C. gloeosporioides, A. solani, and F. solani with IC₅₀ values of 20.76, 27.58, and 18.60 μ g/mL (Table 2), respectively, than other 4-series derivatives such as 4e and 4l with a fluorine or *t*-butyl group, but had no activity toward B. cinerea. This indicated that para- or orthosubstitution of the benzene ring is not beneficial for the activity. Notably, 4m showed a fungicidal activity against F. solani which was 2-fold of the control hymexazol (IC_{50} of 38.49 μ g/mL). We reasoned that *F. solani* was not sensitive to the Cl atom (4f vs 4m and 4e). Furthermore, within the 4-series derivatives, compound 4f, having a chlorine atom on paraposition of the benzene ring, was the best compound in inhibiting both Cytospora sp. and B. cinerea with IC₅₀ values of 24.91 and 26.82 μ g/mL, respectively, in particular, with inhibition of 4f on Cytospora sp. being much higher than that of the control hymexazol. This suggested the presence of this

| compound — | | | $IC_{50} \pm SD/ (\mu g/mL)$ | | |
|-------------------------------------|------------------|------------------|------------------------------|------------------|------------------|
| | C. s. | C. g. | В. с. | A. s. | F. s. |
| 1 | NA | 83.15 ± 12.63 | >100 | >100 | NA |
| 2 | >100 | 80.29 ± 2.03 | 68.11 ± 3.70 | >100 | >150 |
| 4a | >100 | >120 | 68.88 ± 5.90 | >100 | 82.36 ± 5.54 |
| 4b | >100 | 70.62 ± 0.81 | >100 | >100 | >100 |
| 4c | 50.68 ± 1.17 | >120 | 89.58 ± 9.54 | >100 | 39.05 ± 7.08 |
| 4e | 58.25 ± 1.34 | >100 | >120 | 69.35 ± 4.51 | 31.52 ± 1.41 |
| 4f | 24.91 ± 0.34 | 41.26 ± 2.25 | 26.82 ± 2.77 | 62.46 ± 1.10 | >100 |
| 4j | 52.58 ± 1.53 | 49.71 ± 3.58 | >150 | >150 | >150 |
| 4m | 50.04 ± 1.03 | 20.76 ± 0.67 | >150 | 27.58 ± 0.59 | 18.60 ± 1.10 |
| 4n | 54.30 ± 1.44 | 55.69 ± 0.18 | 63.72 ± 10.03 | >100 | 72.97 ± 0.84 |
| 5a | NA | >150 | 50.91 ± 2.65 | NA | NA |
| 5b | 30.97 ± 1.12 | 11.38 ± 0.90 | 57.71 ± 3.51 | >100 | 40.15 ± 0.76 |
| 5c | NA | 22.29 ± 0.69 | >100 | NA | NA |
| 6 | 22.48 ± 0.44 | 28.03 ± 1.69 | >100 | 27.95 ± 3.52 | 23.34 ± 2.08 |
| 7f | NA | NA | 13.36 ± 1.35 | NA | NA |
| 7 n | NA | NA | 69.10 ± 2.57 | NA | NA |
| Hy | >100 | >100 | 8.92 ± 0.44 | 14.03 ± 0.14 | 38.49 ± 6.95 |
| ^{<i>a</i>} NA. not active. | | | | | |

Table 2. Antifungal Activity of Some Compounds against Five Phytopathogens^a

Scheme 2. Possible Mechanism for the Formation of 3



chlorine atom on para-position in the benzene ring to contribute to enhancing activity. Additionally, compared to intermediate **2**, displacement of the chlorine atom of **2** by varying phenoxyl groups resulted in the general trend of improving inhibitory activity of 4-series compounds to the five fungi due to lower IC₅₀ data (Table 2). For example, inhibitory potency of **4m** to *C. gloeosporioides* increased by approximately 4-fold of **2** with an IC₅₀ of 80.29 μ g/mL.

In case of the 5-series, 5b with a methanesulfonyl group addition exhibited moderate to strong antifungal effects on Cytospora sp., C. gloeosporioides, B. cinerea, and F. solani with IC_{50} values of 30.97, 11.38, 57.71, and 40.15 μ g/mL, respectively, while **5c** selectively inhibited growth of *C. gloeosporioides* with an IC_{50} value of 22.29 μ g/mL but was almost inactive toward the other fungal pathogens. Notably, 5b was 2-fold more active against C. gloeosporioides (IC₅₀ = 11.38 μ g/mL) than 5c with a 4-chlorobenzenesulfonyl moiety, which were both superior to the reference (IC₅₀ > 100 μ g/mL). In addition, **5a** gave moderate activity toward B. cinerea with an IC₅₀ value of 50.91 \pm 2.65 μ g/mL but had no antifungal effects on other fungal pathogens. These findings indicated that introduction of a small bulky sulfonyl group at the NH-position of the benzimidazole ring appeared to be more favorable for increasing activity against C. gloeosporioides (5b and 5c vs 5a). These structures provide new templates for the potential treatment and management of anthracnose diseases.

However, only two phenoxyl ether derivatives 7f and 7n of intermediate 6 selectively inhibited the mycelial growth of *B. cinerea* (IC₅₀ of 13.36 and 69.10 μ g/mL, respectively), with 7f being 5-fold stronger than 7n and being comparable to hymexazol (IC₅₀ = 8.92 μ g/mL) in antifungal potency (Table 2).

Both **7f** and **7n** presented much higher inhibitory activity against *B. cinerea* than the parent compound **6**. This suggested that the chlorine atom at para-position in the phenyl ring of **7f** plays an important role in the fungicidal activity to *B. cinerea*. Intriguingly, in comparison with **6**, **7f**, and **7n** had no fungicidal activity against the other pathogenic species tested *Cytospora* sp., *C. gloeosporioides, A. solani*, and *F. solani* since **7f** and **7n** were devoid of the chlorine group of **6**. These findings indicated that *B. cinerea* is more susceptible to **7f** than to **7n** and that the chlorine atom of **6** to be a structural feature important for improved antifungal activity to the other organisms.

In conclusion, we have reported the synthesis of a series of 2-chloromethyl-1H-benzimidazole derivatives as well as the ability of these compounds to inhibit growth of five fungal phytopathogenes tested. Many of the synthetic compounds tested, including intermediate 6, were found to have significant antifungal activity against certain phytopathogenic fungi in vitro. Compounds 4m and 6 displayed higher antifungal activity against Cytospora sp., C. gloeosporioides, A. solani, and F. solani. 5c and 7f also exhibited strong antifungal properties with relatively high selectivity against C. gloeosporioides and B. cinerea with IC₅₀ values of 22.29 and 13.36 μ g/mL, respectively. Compound 5b gave substantially strong antifungal effects on C. gloeosporioides with an IC_{50} value of 11.38 μ g/mL, which is much better than that of hymexazol, a wellknown commercial fungicide. Taken together, compounds 4m, 5b, and 7f were demonstrated to possess the most potent inhibition of the fungal plant pathogens tested in the present study and could be potential lead structures for further discovery of novel antifungal agrochemicals.

ASSOCIATED CONTENT

Supporting Information

HRMS and NMR spectra of new synthetic compounds, and (HR)MS and NMR data of known compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*Tel: +86-29-87092335; e-mail: anlingzh@nwsuaf.edu.cn; jinminggao@nwsuaf.edu.cn.

Funding

This work was financially supported by grants from the National Natural Science Foundation of China (No. 30971882), the Program of Natural Science Basis Research in Shaanxi (No. 2009JM3010), and Shaanxi Province Science and Technology (No. 2011k02–07).

Notes

The authors declare no competing financial interest.

REFERENCES

(1) Savary, S.; Teng, P. S.; Willocquet, L.; Nutter, , F. W., Jr Quantification and modeling of crop losses: A review of purposes. *Annu. Rev. Phytopathol.* **2006**, *44*, 89–112.

(2) Bräse, S.; Encinas, A.; Keck, J.; Nising, C. F. Chemistry and biology of mycotoxins and related fungal metabolites. *Chem. Rev.* 2009, 109, 3903–3990.

(3) Meepagala, K. M.; Kuhajek, J. M.; Sturtz, G. D.; Wedge, D. E.; Vulgarone, B. The antifungal constituent in the steam-distilled fraction of *Artemisia douglasiana*. J. Chem. Ecol. **2003**, *29*, 1771–1780.

(4) Pan, Z. Z.; Zhu, Y. J.; Yu, X. J.; Lin, Q. F.; Xiao, R. F.; Tang, J. Y.; Chen, Q. X.; Liu, B. Synthesis of 4'-thiosemicarbazonegriseofulvin and its effects on the control of enzymatic browning and postharvest disease of fruits. J. Agric. Food Chem. **2012**, 60, 10784–10788.

(5) Saremi, H.; Okhovvat, S. M. Mycotoxin producing *Fusarium* species associated with plant disease on potato, wheat, corn and animal diseases in northwest Iran. *Commun. Agric. Appl. Biol. Sci.* 2006, 71, 1175–1185.

(6) Xu, H.; Fan, L.-L. Antifungal agents. Part 4: Synthesis and antifungal activities of novel indole [1,2-c]-1,2,4-benzotriazine derivatives against phytopathogenic fungi in vitro. *Eur. J. Med. Chem.* **2011**, 46, 364–369.

(7) Amrutkar, S. V., Sunil V; Bhagat, U. D; Pargharmol., P.; Kotgire, S. S. Synthesis and antifungal activity of 1alkyl/h2[4(alkyl/ arylpiperazin1yl)methyl]benzimidazole derivatives. *Int. J. Pharm. Pharm. Sci.* **2010**, *2*, 84–92.

(8) Ansari, K. F.; Lal, C. Synthesis, physicochemical properties and antimicrobial activity of some new benzimidazole derivatives. *Eur. J. Med. Chem.* **2009**, *44*, 4028–4033.

(9) Vaidya, S. D.; Kumara, B. V. S.; Kumar, U. N. B. R. V. Synthesis, anti-bacterial, anti-asthmatic and anti-diabetic activities of novel N-substituted-2-(benzo[d]isoxazol-3-ylmethyl)-1H-benzimidazoles. *J. Heterocyclic Chem.* **2007**, *44*, 685–691.

(10) Ma, Y. T.; Fan, H. F.; Gao, Y.; Li, H.; Zhang, A. L.; Gao, J. M. Natural products as sources of new fungicides (I): Synthesis and antifungal activity of acetophenone derivatives against phytopathogenic fungi. *Chem. Biol. Drug. Des.* **2012**, DOI: 10.1111/cbdd.12064.

(11) Njoya, Y.; Boufatah, N.; Gellis, A.; Rathelot, P. Microwaveassisted synthesis of new benzimidazoles. *Heterocycles* **2002**, *57*, 1423– 1432.

(12) Sheng, C.; Che, X.; Wang, W.; Wang, S. Design and synthesis of antifungal benzohetercyclic derivatives by scaffold hopping. *Eur. J. Med. Chem.* **2011**, *46*, 1706–1712.

(13) Skolnik, H.; Miller, J. G.; Day, A. R. The allylic character of 2-(a-chloroalky1)-benzimidazoles. J. Am. Chem. Soc. **1943**, 65, 1854–1858.

(14) Popov, I. I.; Narezhnaya, V. N.; Zubenko, A. A. Research on unsaturated azole derivatives. *Khim. Geterotsikl. Soedin.* **1978**, *8*, 1104–1107.

(15) Khan, K. M.; Shah, Z.; Ahmad, V. U.; Ambreen, N.; Khan, M.; Taha, M.; Rahim, F.; Noreen, S.; Perveen, S.; Choudhary, M. I.; Voelter, W. 6-Nitrobenzimidazole derivatives: Potential phosphodiesterase inhibitors: Synthesis and structure-activity relationship. *Bioorg. Med. Chem.* **2012**, *20*, 1521–1526.

(16) RamLa, M. M.; Omar, M. A.; El-Khamry, A. M.; El-Diwani, H. I. Synthesis and antitumor activity of 1-substituted-2-methyl-5-nitrobenzimidazoles. *Bioorg. Med. Chem.* **2006**, *14*, 7324–7332.

(17) Sanchez-Moreno, M. J.; Gomez-Coca, R. B.; Fernandez-Botello, A.; Ochocki, J. Synthesis and acid-base properties of (1*H*-benzimidazol-2-yl-methyl)phosphonate (Bimp2-). Evidence for intra-

molecular hydrogen-bond formation in aqueous solution between (N-1)H and the phosphonate group. *Org. Biomol. Chem.* **2003**, *1*, 1819–1826.

(18) Okamoto, Y.; Ueda, T. Acylation of 2-cyanomethylbenzimidazole. *Chem. Pharm. Bull.* **1977**, *11*, 3087–3089.

(19) Li, H.-Q.; Li, X.-J.; Wang, Y.-L.; Zhang, Q.; Zhang, A.-L.; Gao, J.-M.; Zhang, X.-C. Antifungal metabolites from *Chaetomium globosum*, an endophytic fungus in *Ginkgo biloba*. *Biochem. Syst. Ecol.* **2011**, *39*, 876–879.

(20) Li, X. J.; Zhang, Q.; Zhang, A. L.; Gao, J. M. Metabolites from *Aspergillus fumigatus*, an endophytic fungus associated with *Melia azedarach*, and their antifungal, antifeedant, and toxic activities. *J. Agric. Food Chem.* **2012**, *60*, 3424–3431.

(21) Li, X. J.; Shi, X. W.; Shuai, Q.; Gao, J. M.; Zhang, A. L. Bioactive metabolites from biotransformation of paeonol by the white-rot basidiomycete *Coriolus versicolor*. *Nat. Prod. Commun.* **2011**, *6*, 1129–1130.

(22) Wright, J. B. The chemistry of the benzimidazoles. Chem. Rev. 1951, 48, 397–541.